SNN vs. ENOV, ALGN, ZBH, SOLV, NTRA, SRPT, UTHR, UHS, EXAS, and CTLT
Should you be buying Smith & Nephew stock or one of its competitors? The main competitors of Smith & Nephew include Enovis (ENOV), Align Technology (ALGN), Zimmer Biomet (ZBH), NYSE:SOLV (SOLV), Natera (NTRA), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Universal Health Services (UHS), Exact Sciences (EXAS), and Catalent (CTLT). These companies are all part of the "medical" sector.
Enovis (NYSE:ENOV) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, community ranking, media sentiment, risk, profitability, earnings and institutional ownership.
Smith & Nephew received 420 more outperform votes than Enovis when rated by MarketBeat users. However, 58.97% of users gave Enovis an outperform vote while only 54.29% of users gave Smith & Nephew an outperform vote.
Enovis has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.
Smith & Nephew has higher revenue and earnings than Enovis.
Enovis currently has a consensus target price of $75.43, suggesting a potential upside of 36.50%. Given Smith & Nephew's stronger consensus rating and higher possible upside, research analysts clearly believe Enovis is more favorable than Smith & Nephew.
98.5% of Enovis shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew shares are held by institutional investors. 2.4% of Enovis shares are held by company insiders. Comparatively, 1.0% of Smith & Nephew shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Smith & Nephew has a net margin of 0.00% compared to Smith & Nephew's net margin of -1.95%. Smith & Nephew's return on equity of 3.84% beat Enovis' return on equity.
In the previous week, Enovis had 2 more articles in the media than Smith & Nephew. MarketBeat recorded 5 mentions for Enovis and 3 mentions for Smith & Nephew. Enovis' average media sentiment score of 1.03 beat Smith & Nephew's score of 0.99 indicating that Smith & Nephew is being referred to more favorably in the news media.
Summary
Enovis beats Smith & Nephew on 10 of the 16 factors compared between the two stocks.
Get Smith & Nephew News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Smith & Nephew Competitors List
Related Companies and Tools
